Catalytic antibodies to HIV: physiological role and potential clinical utility.

Immunoglobulins (Igs) in uninfected humans recognize residues 421-433 located in the B cell superantigenic site (SAg) of the HIV envelope protein gp120 and catalyze its hydrolysis by a serine protease-like mechanism. The catalytic activity is encoded by germline Ig variable (V) region genes, and is expressed at robust levels by IgMs and IgAs but poorly by IgGs. Mucosal IgAs are highly catalytic and neutralize HIV, suggesting that they constitute a first line of defense against HIV. Lupus patients produce the Igs at enhanced levels. Homology of the 421-433 region with an endogenous retroviral sequence and a bacterial protein may provide clues about the antigen driving anti-SAg synthesis in lupus patients and uninfected subjects. The potency and breadth of HIV neutralization revives hopes of clinical application of catalytic anti-421-433 Igs as immunotherapeutic and topical microbicide reagents. Adaptive improvement of anti-SAg catalytic Igs in HIV infected subjects is not customary. Further study of the properties of the naturally occurring anti-SAg catalytic Igs should provide valuable guidance in designing a prophylactic vaccine that amplifies protective catalytic immunity to HIV.

[1]  E. Meese,et al.  Human endogenous retroviruses in the primate lineage and their influence on host genomes , 2005, Cytogenetic and Genome Research.

[2]  A mechanism-based probe for gp120-Hydrolyzing antibodies. , 2002, Bioorganic & medicinal chemistry letters.

[3]  H. Sheppard,et al.  Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection. , 2007, AIDS research and human retroviruses.

[4]  Y. Nishiyama,et al.  Antibodies to the superantigenic site of HIV-1 gp120: hydrolytic and binding activities of the light chain subunit. , 2007, Molecular immunology.

[5]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[6]  T. Vogl,et al.  T lymphocytes in patients with primary vasculitis: expansion of CD8+ T cells with the propensity to activate polymorphonuclear neutrophils. , 2008, Rheumatology.

[7]  L. Lopalco,et al.  Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. , 2002, Journal of acquired immune deficiency syndromes.

[8]  Y. Nishiyama,et al.  Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120. , 2003, Vaccine.

[9]  S. Paul,et al.  Site-directed mutagenesis of proteolytic antibody light chain. , 1995, Journal of molecular biology.

[10]  D. Wallace,et al.  False-positive human immunodeficiency virus testing in patients with lupus erythematosus. , 1993, Seminars in arthritis and rheumatism.

[11]  L. Mouthon,et al.  Intravenous immunoglobulins in infectious diseases: where do we stand? , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  N. Haigwood,et al.  Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. , 1996, Immunology letters.

[13]  E. Çağlar,et al.  Anti-Scl-70 Antibodies in Autoimmune Hypothyroidism , 2008, The Journal of international medical research.

[14]  G. Silverman.  B cell superantigens: possible roles in immunodeficiency and autoimmunity. , 1998, Seminars in immunology.

[15]  D. Burton,et al.  Molecular selection of human antibodies with an unconventional bacterial B cell antigen. , 1993, Journal of immunology.

[16]  H. Hashimoto,et al.  The possible role of interleukin-16 in the low incidence of HIV infection in patients with systemic lupus erythematosus , 2000, Lupus.

[17]  G. Pantaleo,et al.  The moving target: mechanisms of HIV persistence during primary infection. , 1999, Immunology today.

[18]  D. Ho,et al.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.

[19]  W. Shearer,et al.  gp120- and TNF-alpha-induced modulation of human B cell function: proliferation, cyclic AMP generation, Ig production, and B-cell receptor expression. , 2000, The Journal of allergy and clinical immunology.

[20]  J. Sodroski,et al.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.

[21]  D. Richman,et al.  HIV evolution and escape. , 2004, Transactions of the American Clinical and Climatological Association.

[22]  N. Rote,et al.  Expression of endogenous HIV-1 crossreactive antigens within normal human extravillous trophoblast cells. , 1995, Journal of reproductive immunology.

[23]  F. Arnett,et al.  Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library , 2004, AIDS.

[24]  Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies , 2006, Journal of molecular recognition : JMR.

[25]  M. Sun,et al.  Innate antibody catalysis. , 1999, Molecular immunology.

[26]  R. Detels,et al.  Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission. , 1996, The Journal of clinical investigation.

[27]  J. Berzofsky,et al.  Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease. , 1994, AIDS Research and Human Retroviruses.

[28]  R. Massey,et al.  Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. , 1989 .

[29]  E. Holmes,et al.  On the origin and evolution of the human immunodeficiency virus (HIV) , 2001, Biological reviews of the Cambridge Philosophical Society.

[30]  A. Haase.  Perils at mucosal front lines for HIV and SIV and their hosts , 2005, Nature Reviews Immunology.

[31]  L. Goodglick,et al.  Mapping the Ig superantigen-binding site of HIV-1 gp120. , 1995, Journal of immunology.

[32]  Y. Nishiyama,et al.  Antibodies as defensive enzymes , 2005, Springer Seminars in Immunopathology.

[33]  R. Sékaly.  The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? , 2008, The Journal of experimental medicine.

[34]  H. Urnovitz,et al.  Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease , 1996, Clinical microbiology reviews.

[35]  J. Moore,et al.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 , 1994, Journal of virology.

[36]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[37]  A. Edmundson,et al.  Naturally Occurring Proteolytic Antibodies , 2004, Journal of Biological Chemistry.

[38]  D. Isenberg,et al.  Structural basis of the gp120 superantigen-binding site on human immunoglobulins. , 1998, Journal of immunology.

[39]  M. Zouali,et al.  Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  Y. Nishiyama,et al.  Specific HIV gp120-cleaving Antibodies Induced by Covalently Reactive Analog of gp120* , 2003, Journal of Biological Chemistry.

[41]  H. Sheppard,et al.  Phase I/II Study of a Candidate Vaccine Designed Against the B and E Subtypes of HIV-1 , 2004, Journal of acquired immune deficiency syndromes.

[42]  S. Said,et al.  New evidence for transmitter role of VIP in the airways: impaired relaxation by a catalytic antibody. , 2002, Pulmonary pharmacology & therapeutics.